
NASDAQHealthcareBiotechnology
Latest quote
$84.55
−$0.28 · -0.33%
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Previous close
$84.55
−$0.28 · -0.33%
Regular session · ET · Market data may be delayed.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Day range
Current $84.55
52-week range
Current $84.55
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
32
Expensive
Sentiment
58
Mixed
Risk
35
Moderate Risk
Momentum
70
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Day range
Current $84.55
52-week range
Current $84.55
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$136.5
61.44% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Sep 12, 2023 | 1:16 | — | — |
Effective Sep 12, 2023
1:16
Funds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR S&P Biotech ETFXBI120.03M1.25%9.64B USD0.35%$140.18-2.73%
Vanguard Morningstar Total Stock Market ETFVTI109.72M0.01%689.3B USD0.03%$340.02-3.52%
iShares Russell 2000 ETFIWM105.28M0.14%71.54B USD0.19%$256.61-2.88%
Vanguard Extended Market ETFVXF52.31M0.06%30.2B USD0.05%$211.44-3.21%
Vanguard Morningstar Small-Cap ETFVB49.02M0.03%78.7B USD0.03%$270.68-2.56%
iShares Russell 2000 Growth ETFIWO37.91M0.29%12.73B USD0.24%$320.43-3.57%
Vanguard Morningstar Small-Cap Value ETFVBR31.89M0.05%37.1B USD0.05%$231.38-2.02%
Schwab U.S. Small-Cap ETFSCHA24.71M0.12%20.45B USD0.03%$30.51-2.83%
State Street SPDR S&P Biotech ETFXBI
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
Vanguard Extended Market ETFVXF
Vanguard Morningstar Small-Cap ETFVB
iShares Russell 2000 Growth ETFIWO
Vanguard Morningstar Small-Cap Value ETFVBR
Schwab U.S. Small-Cap ETFSCHAAI-generated and delayed market data for informational and educational purposes only. Not investment advice.